• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Omecamtiv mecarbil may be associated with decreased risk of heart-failure events

byThomas SuandDeepti Shroff Karhade
January 26, 2021
in Cardiology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients who received omecamtiv mecarbil had slightly fewer systolic heart failure exacerbations compared to those who received placebo.

2. Serious adverse events occurred equally frequently in both groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: At present, no medications that directly stimulate systolic function have been shown to improve health outcomes in patients who have heart failure with a reduced ejection fraction. Several calcitropes have been able to augment measures of cardiac performance, but the increase in the magnitude of intracellular calcium transients was found to also heighten the risk of myocardial ischemia, ventricular arrhythmias, and death. Omecamtiv mecarbil is the first of a class of myotropes called cardiac myosin activators which selectively enhance binding of the head domain to actin filaments, thereby increasing cardiac output without modulating calcium availability. In a phase 2 trial, this medication appeared to be effective in increasing stroke volume and reducing both heart rate and plasma natriuretic peptide levels. Based on these findings, the present phase 3 study was designed to evaluate the effect of omecamtiv mecarbil treatment on the incidence of heart-failure events and cardiovascular death in patients with a reduced ejection. While both groups had similar mortality from cardiovascular causes as well as all causes, the omecamtiv mecarbil group had significantly fewer instances of the composite primary outcome of heart-failure events and cardiovascular death. Further, adverse events generally occurred at similar rates in both groups, although a between-group difference in favor of the omecamtiv mecarbil group was observed with regard to stroke. While this study involved several thousand patients, it was limited by a lack of racial heterogeneity and an underrepresentation of women. Overall, these findings suggested that omecamtiv mecarbil may improve clinical outcomes in patients with systolic heart failure.

Click here to read the study in NEJM

Relevant Reading: Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

In-Depth [randomized controlled trial]: This double-blind study, termed Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure (GALACTIC-HF), was conducted from January 6, 2017 to August 7, 2020 and involved 8232 individuals between 18 and 85 years of age who had symptomatic heart failure with a left ventricular ejection fraction of 35% or less. Patients were randomly assigned in a 1:1 ratio to receive either placebo or oral omecamtiv mecarbil at a dose of 25 mg, 37.5 mg, or 50 mg twice daily according to the plasma levels of the drug. The primary outcome was a composite of cardiovascular death or a heart-failure event, defined as an urgent clinic visit, emergency department visit, or hospitalization leading to treatment intensification beyond a change in diuretic therapy. This composite outcome occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.86 to 0.99; P=0.03). The individual outcome of death from cardiovascular causes occurred in 808 patients (19.6%) in the omecamtiv mecarbil group and in 798 patients (19.4%) in the placebo group (HR, 1.01; 95% CI, 0.92 to 1.11; P=0.86). All-cause mortality was also nearly identical between groups (1067 patients vs. 1065 patients; HR, 1.00; 95% CI, 0.92 to 1.09). With regard to safety, both groups had similar numbers of patients for whom treatment was temporarily withheld because of concern of active myocardial infarction or ischemia (103 vs. 101) as well as patients for whom treatment was discontinued due to adverse events (371 vs. 382). The omecamtiv mecarbil group also had a slightly greater increase in median cardiac troponin I and slightly greater decreases from baseline in heart rate and median NT-proBNP; all other laboratory measures were similar between groups.

RELATED REPORTS

Dapagliflozin efficacious and safe in treating heart failure

Interatrial shunt device not effective in patients with symptomatic heart failure

#VisualAbstract: Effectiveness of sacubitril-valsartan in post-myocardial infarction management compared to ramipril

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No articleshould be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: heart failureomecamtiv mecarbil
Previous Post

Early high-titer plasma therapy may reduce progression of COVID-19 in older patients

Next Post

Clinical outcomes of COVID-19 in patients 6-months after hospital discharge in Wuhan, China

RelatedReports

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Dapagliflozin efficacious and safe in treating heart failure

May 13, 2022
30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Interatrial shunt device not effective in patients with symptomatic heart failure

March 29, 2022
StudyGraphics

#VisualAbstract: Effectiveness of sacubitril-valsartan in post-myocardial infarction management compared to ramipril

February 10, 2022
Cardiology

Sacubitril or valsartan versus standard medical therapies in patients with heart failure with preserved ejection fraction: PARALLAX trial

November 17, 2021
Next Post
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Clinical outcomes of COVID-19 in patients 6-months after hospital discharge in Wuhan, China

#VisualAbstract: Occult Blood in Feces Is Associated With an Increased Risk of Ischemic Stroke and Myocardial Infarction

#VisualAbstract: Oral azacytidine improves survival outcomes as maintenance therapy for patients with acute myeloid leukemia

Eczema more prevalent among older adults than previously thought

Association of potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.